BioCryst halts enrollment in all studies for its lead pipeline candidate — shares crash

BioCryst is taking a beating Friday morning after reporting it would pause enrollment in three studies for its lead pipeline program.

In a terse statement put out right before the market opened, the Durham, NC-based biotech said it discovered elevated serum creatinine levels in some patients, and will halt recruitment while it investigates. Elevated creatine levels can be a sign of kidney dysfunction.